重度吸烟者低剂量CT肺癌筛查的成本效果:微模拟模型研究
该研究采用适配的微模拟模型,从健康保险视角评估荷兰重度吸烟者终生低剂量CT肺癌筛查的成本效果。结果表明,男性每年筛查(55-80岁)、女性每两年筛查(50-80岁)为最优方案,相比不筛查的ICER分别为27.6和21.1千欧元/生命年,肺癌死亡率分别降低15.9%和10.6%。
要点
- 男性最优方案为55-80岁每年筛查,ICER为27.6千欧元/生命年。
- 女性最优方案为50-80岁每两年筛查,ICER为21.1千欧元/生命年。
- 所有评估方案ACER均低于60千欧元/生命年的可接受阈值。
核心结论
- 在高风险人群中,低剂量CT肺癌筛查具有成本效果。
- 最优筛查方案依赖于性别。
研究设计与样本
- 采用适配的微模拟模型,模拟10万男性与10万女性重度吸烟者终生队列。
- 从健康保险视角评估,对照为不筛查。
主要发现
- 评估方案ACER男性17.7-32.4千欧元/生命年,女性17.8-32.1千欧元/生命年。
- 肺癌死亡率降低男性9.3%-16.8%,女性7.8%-13.7%。
- 男性最优方案(每年55-80岁)相比前一有效替代方案ICER为51.6千欧元/生命年。
- 女性最优方案(每两年50-80岁)相比前一有效替代方案ICER为45.8千欧元/生命年。
- 相比不筛查,最优方案ICER男性27.6千欧元/生命年,女性21.1千欧元/生命年。
关键数值与推荐
- 成本效果阈值假定为60千欧元/生命年。
- 最优方案死亡率降低男性15.9%,女性10.6%。
临床怎么用
- 对重度吸烟男性可考虑55-80岁每年低剂量CT筛查。
- 对重度吸烟女性可考虑50-80岁每两年低剂量CT筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality. The aim of this study was to evaluate the cost-effectiveness of lung cancer screening with LDCT in a high-risk population. METHODS: The study used an adapted microsimulation model in a cohort of Dutch heavy smokers for a lifetime horizon from a health insurance perspective. The main outcomes included average cost-effectiveness ratio (ACER), incremental cost-effectiveness ratio (ICER) and lung cancer mortality reduction. The comparator was no screening. Scenarios with different screening intervals and starting and stopping ages were evaluated for 100,000 male heavy smokers and 100,000 female heavy smokers. A cost-effectiveness threshold of 60 k€ per life year gained (LYG) was assumed acceptable. RESULTS: The evaluated screening scenarios yielded ACERs ranging from 17.7 to 32.4 k€/LYG for men and from 17.8 to 32.1 k€/LYG for women. The lung cancer mortality reduction ranged from 9.3% to 16.8% for men and from 7.8% to 13.7% for women. The optimal screening scenario was annual screening from 55 to 80 years for men and biennial screening from 50 to 80 years for women, with an ICER of 51.6 and 45.8 k€ per LYG compared with its previous efficient alternative, respectively. Compared with no screening, the optimal screening scenario yielded an ICER of 27.6 k€/LYG for men and 21.1 k€/LYG for women. The mortality reduction of lung cancer was 15.9% for men and 10.6% for women. CONCLUSIONS: Lung cancer LDCT screening is cost-effective in a high-risk population. The optimal screening scenario is dependent on sex.
引用
- Du Y, Sidorenkov G, Heuvelmans MA, et al. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. Eur J Cancer. 2020. PMID: 32563896. doi:10.1016/j.ejca.2020.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。